Moteur de recherche d’entreprises européennes
Financement de l’UE (7 999 949 €) : 4-DANS LA COURSE AU POUMON : vers des INvitations INvidudually personnalisées, des INtervals de dépistage et des stratégies intégrées de réduction de la … Hor01/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
4-DANS LA COURSE AU POUMON : vers des INvitations INvidudually personnalisées, des INtervals de dépistage et des stratégies intégrées de réduction de la comorbidité dans le dépistage du cancer du poumon
With 338,000 EU-deaths annually, lung cancer is a devastating problem. CT screening has the potential to prevent ten-thousands of lung cancer deaths annually. The positive results of the Dutch-Belgian screening trial (NELSON), with relatively low referral rates, and the NLST in the USA provided conclusive evidence. However, implementation is likely to be limited, slow and of variable quality throughout Europe, and current guidelines could easily require up to 25 million CT screens annually. The most optimal strategy in risk-based lung-thoracic screening is still unknown regarding the optimal and most cost-effective (e.g., targeted) strategy 1) to recruit, 2) to integrate smoking cessation and co-morbidity-reducing services, and 3) to determine the (risk-based) screening interval. Personalised regimens based on the baseline CT result can potentially retain 85% of the mortality reduction achievable through screening at 45% less screens, thus potentially saving much unnecessary harm associated with screening, and 0.5-1 billion Euros per year. The heart of 4-IN-THE-LUNG-RUN is a randomised controlled trial amongst about 24,000 individuals evaluating whether it is safe to have risk-based less intensive screening intervals after a negative baseline CT. Various methods to improve participation of hard-to-reach individuals will be assessed in five different healthcare settings. Innovative co-morbidity reducing strategies will be tested including other markers on CT imaging, as Calcium Score and COPD. Cost impact and cost-effectiveness analyses using a natural history model will steer implementation. The experienced consortium will strongly interact with key stakeholders, and discuss interim results with key other international initiatives on CT screening, biomarkers, and smoking cessation practices. This proposal will form the evidence base for risk-based lung cancer screening with huge benefits for the EU, on health outcomes, cost savings, and innovation in the long run.
| DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG | 852 444 € |
| ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | 2 797 465 € |
| Fondazione Irccs Istituto Nazionale DEI Tumori | 743 285 € |
| Institut Catala D'Oncologia | 326 575 € |
| INSTITUTE FOR DIAGNOSTIC ACCURACY CONSULTING B.V. | 0,00 € |
| INSTITUTE FOR DIAGNOSTIC ACCURACY RESEARCH B.V. | 2 726 500 € |
| Institut Gustave Roussy | 125 750 € |
| The University of Nottingham | 241 240 € |
| UNIVERSITAETSKLINIKUM ESSEN | 102 470 € |
| University College London | 84 220 € |
https://cordis.europa.eu/project/id/848294
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.